CALT - Calliditas bid to get full FDA nod for kidney drug granted priority review
2023-08-18 06:51:30 ET
More on Calliditas
- Calliditas: Riding The Setanaxib Wave And Betting On Tarpeyo's Triumph
- Calliditas Therapeutics: First Quarter Not As Bad As It Looks
- Calliditas interim phase 2 data positive for head and neck cancer asset setanaxib
- Calliditas seeking full approval of Tarpeyo from FDA for IgA nephropathy
- Everest's kidney disease drug Nefecon gets review in Singapore
For further details see:
Calliditas bid to get full FDA nod for kidney drug granted priority review